Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Neoplasms, Plasma Cell 1Myelodysplastic Syndromes 1Lung Neoplasms 1Leukemia 1Hematologic Neoplasms 1Graft vs Host Disease 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cyclophosphamide 64Tacrolimus 55Methotrexate 46Mycophenolic Acid 39Cyclosporine 37fludarabine phosphate 35Busulfan 35Antilymphocyte Serum 32fludarabine 29Sirolimus 26Melphalan 23Peripheral Blood Stem Cell Transplantation 22Radiotherapy 21Methylprednisolone 21Whole-Body Irradiation 19Filgrastim 17thymoglobulin 14Thiotepa 11Stem Cell Transplantation 10Rituximab 10ruxolitinib 9Granulocyte Colony-Stimulating Factor 9Prednisone 7Hematopoietic Stem Cell Transplantation 7Etoposide 7Cord Blood Stem Cell Transplantation 7Alemtuzumab 7Transplantation 6Pentostatin 6Cytarabine 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Graft vs Host Disease × KRN 7000 × Clear all
NCT01379209 2019-10-23

Intravenous Administration of RGI-2001 in Patient Undergoing Allogenic Hematopoietic Stem Cell Transplantation (AHSCT)

Regimmune Corporation

Phase 1/2 Completed
68 enrolled
MyeloidOther hematologic neoplasm

Graft vs Host Disease, Leukemia, Myelodysplastic Syndromes, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡